These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32982341)

  • 1. Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease.
    Mladsi D; Barnett C; Aggarwal K; Vredenburg M; Dieterich D; Kim R
    Clinicoecon Outcomes Res; 2020; 12():515-526. PubMed ID: 32982341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.
    Poordad F; Terrault NA; Alkhouri N; Tian W; Allen LF; Rabinovitz M
    Int J Hepatol; 2020; 2020():5421632. PubMed ID: 32047671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
    Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
    World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 10. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Estcourt LJ; Stanworth SJ; Doree C; Hopewell S; Trivella M; Murphy MF
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010983. PubMed ID: 26576687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia.
    Eguchi Y; Takahashi H; Mappa S; Santagostino E
    Hepatol Res; 2022 Apr; 52(4):371-380. PubMed ID: 35134259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    Desborough M; Hadjinicolaou AV; Chaimani A; Trivella M; Vyas P; Doree C; Hopewell S; Stanworth SJ; Estcourt LJ
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012055. PubMed ID: 27797129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
    Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
    Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
    Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Crighton GL; Estcourt LJ; Wood EM; Trivella M; Doree C; Stanworth S
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010981. PubMed ID: 26422767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
    Estcourt LJ; Stanworth S; Doree C; Trivella M; Hopewell S; Blanco P; Murphy MF
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010984. PubMed ID: 26505729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.